Search Results - therapeutics+%3e+oncology+%3e+oncology+immunotherapy

41 Results

Sort By:

Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)

UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...

Published: 3/6/2024 | Inventor(s): Cun-Yu Wang, Jia Lingfei

Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor

Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing

Targeting Prostate Cancer with a Novel T-Cell Receptor and Tissue-Specific Cancer Antigens for Improved Immune Response (UCLA Case No. 2022-070)

Researchers from UCLA’s Department of Microbiology, Immunology, & Molecular Genetics (MIMG), and the department of Molecular and Medical Pharmacology have identified a set of tissue-specific antigens which have been used to isolate and characterize a group of novel T-cell receptors (TCRs) which target prostate cancer specifically. Furthermore,...

Published: 2/26/2024 | Inventor(s): Owen Witte, Zhiyuan Mao, Jami Witte, Pavlo Nesterenko, John Lee

Keywords(s): Cancer, cancer antigen, Peptide, peptides, prostate cancer, protein, t-cells

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

New Fusion Molecule Based on Novel TAA Variant (UCLA Case No. 2007-217)

BACKGROUND: Renal cell carcinoma (RCC) affects approximately 39,000 Americans and causes an estimated 13,000 deaths per year. Metastatic RCC poses a therapeutic challenge because of its resistance to conventional modes of therapy. Approximately one third of RCC patients will present at the metastatic stage and one third of patients with localized disease...

Published: 2/16/2024 | Inventor(s): Arie Belldegrun, Zhenhua Li

Keywords(s): Cancer, Immunotherapy, Renal, Renal cell carcinoma, renal diseases

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Renal

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

Combination of Supercharged NK with Supercharged Gamma Delta T Cells and Supercharged CD8+ T Cells and Super Charged iNKT Cells Should Eliminate Both (UCLA Case No. 2022-322)

SUMMARY: Researchers at UCLA’s School of Dentistry have developed methods and protocols for culturing and priming various immune cells into a “supercharged” phenotype. The studied cell types include NK and iNKT cells, gamma delta T cells, and CD8+ T cells. When deployed in combination, these supercharged cells were found to eliminate...

Published: 7/19/2023 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2022-129 Development of Nano-Delivered CXCR4 Antagonist Carrier to Affect Tumor Microenvironment

SUMMARY: UCLA researchers in the David Geffen School of Medicine have developed a nanocarrier platform to deliver drugs that block CXCR4 directly in tumor microenvironments, with an impact on immune cell trafficking and reducing the tumor’s metastatic burden. BACKGROUND: Cancer remains among the leading causes of death worldwide, and its burden...

Published: 2/5/2024 | Inventor(s): Andre Nel

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2023-043: Enhanced Gamma Delta T Cells for Immunotherapy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel platform to generate potent, high quality Vδ2 T cells at scale for use in cancer immunotherapies. BACKGROUND: With rising cases of cancer in the world, immunotherapies have emerged as a promising and potentially effective therapeutic...

Published: 8/14/2023 | Inventor(s): Lili Yang

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2022-190 Pharmacological Modulation of Chimeric Antigen Receptor (CAR)-T Cell Signaling Pathways to Improve Tumor-Killing Efficacy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel chimeric antigen receptor (CAR)-T cell manufacturing process to prevent premature CAR-T cell dysfunction and enhance CAR-T cell durability and potency. BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy is an emerging pillar...

Published: 8/20/2023 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2022-301 Multi-Specific Engineered Cytokines

SUMMARY: UCLA researchers in the Department of Bioengineering have developed a novel strategy to engineer multivalent cytokine complexes that significantly increase their selectivity towards activating effector or regulatory immune cells and reduce off-target effects in immunotherapy treatments for cancer and autoimmune diseases. BACKGROUND: In recent...

Published: 9/7/2023 | Inventor(s): Aaron Meyer

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2019-839 Self-Modulating T Cells with Robust Anti-Tumor Efficacy and Reduced Propensity for Triggering Severe Cytokine Release Syndrome

SUMMARY: Researchers from UCLA’s Department of Microbiology, Immunology and Molecular Genetics have developed methods for generating self-modulating CAR-T cells which retain robust anti-tumor function whilst having reduced adverse side effects relating to cytokine release syndrome. BACKGROUND: The immunotherapy approach of T-cell engineering...

Published: 9/11/2023 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Autoimmune, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

1 2 3 4 5